[1]
Fleury, I. and Laverdure, E. 2023. Bispecific antibodies and chimeric antigen receptor (CAR) T-cell therapy for indolent lymphoma. Canadian Hematology Today. 2, 3 (Nov. 2023), 5–11. DOI:https://doi.org/10.58931/cht.2023.2338.